The escape of CD19-negative leukemia cells, overexpression of PD-L1 on leukemia cells, and increased numbers of regulatory T cells in combination with an elevated level of lactic dehydrogenase are the possible mechanisms causing the inefficiency of treatment with blinatumomab.144. The gene discussed is CD19; the disease is leukemia.